Metronidazole for Bacterial Vaginosis

BV is a change in the bacteria already living in you rather than an organism arriving from outside. Lactobacillus species, normally dominant, are replaced by anaerobes such as Gardnerella vaginalis, and no single causative agent has been definitively established. The word for that is dysbiosis. It is also common: in a national US survey of women aged 14 to 49, close to one in three tested positive, and recent douching was a strong predictor.

Metronidazole is reduced inside anaerobic bacteria, and the fragments that result damage bacterial DNA. Because its activity sits on anaerobes rather than lactobacilli, it thins the overgrowth without clearing the bacteria you want back. The CDC lists two first-line metronidazole regimens: 500 mg orally twice a day for seven days, or 0.75% gel, one full 5 g applicator intravaginally once a day for five days. Clindamycin 2% cream is the third recommended option. Worth knowing before you fill the tablets: that oral regimen is off-label for BV. The 500 mg tablet label lists trichomoniasis, amebiasis and anaerobic bacterial infections as its approved indications, and BV is not among them, while the only oral metronidazole product FDA has approved for BV is the 750 mg extended-release tablet, which is not what the CDC lists first. The gel is approved for BV. Off-label is not improper and this is the standard of care, but a prescriber should name it as off-label rather than let you assume otherwise.

In a randomized, investigator-blinded trial comparing 0.75% vaginal gel with oral metronidazole in non-pregnant women, BV was clinically eliminated at first follow-up in 83.7% of the intravaginal group and 85.1% of the oral group, and roughly 71% of each group were still clear at the final assessment.

Two routes, essentially one result. Strong odds of ending the episode in front of you, and nothing promised about the months after it.

Those months are where the honest version lives. Following women for a year after a seven-day oral course, 58% had a recurrence of BV by twelve months and 69% had a return of abnormal vaginal flora. Prior BV, keeping the same regular sex partner, and having female partners tracked with recurrence; hormonal contraception looked protective. Metronidazole reliably ends the episode and does much less about the tendency underneath it.

When researchers examined 95 women who had bought an over-the-counter antifungal for a self-diagnosed yeast infection, only 33.7% actually had vulvovaginal candidiasis. Bacterial vaginosis accounted for 18.9%, mixed vaginitis 21.1%, and 13.7% had normal results. A previous clinician-made yeast diagnosis did not improve accuracy, and neither did reading the package. Two in three of those purchases were treating something the buyer did not have.

The split is usually clearer than that record suggests. Itch points away from BV; smell points toward it. Clinically, BV is called when at least three of four criteria line up: homogeneous thin discharge, clue cells on microscopy, vaginal pH above 4.5, and a fishy odor on the whiff test. If your picture points the other way, that is a different drug entirely: see our guide to fluconazole for yeast infections.

In that same head-to-head trial, gastrointestinal side effects were reported by 51.8% of the oral group against 32.7% of the gel group, with comparable clearance either way. That trade is the whole decision for most. Tablets are cheaper, need no applicator at bedtime, and travel better. The gel keeps the drug where the problem is and spares your stomach. Ask yourself whether nausea or inconvenience is the thing you least want for a week.

Beyond metronidazole, the CDC lists clindamycin 2% cream, one 5 g applicator at bedtime for seven days, as a recommended regimen, plus alternatives: oral clindamycin 300 mg twice daily for seven days, clindamycin ovules 100 mg at bedtime for three days, secnidazole 2 g oral granules as a single dose, and tinidazole 2 g once daily for two days or 1 g once daily for five days. Single-dose secnidazole removes the adherence problem, and adds a very different price.

The two first-line regimens are 500 mg orally twice a day for seven days, or 0.75% gel, one full applicator (5 g) intravaginally once a day for five days. Neither gets titrated upward, so there is no dose-finding stretch to sit through. A clinician picks the route from your history, your tolerance for nausea, your pregnancy status, and whatever you have already tried without success. Handling matters more than it sounds. Twelve-hour spacing keeps levels steady, food takes the edge off the nausea, and the gel goes in at bedtime so it stays where it was put. Miss a dose and take it when you remember, unless the next one is close; doubling up does not catch you back up. Stopping early once the smell fades is the most common self-inflicted failure here. None of this is medical advice.

The FDA labeling for metronidazole tablets describes gastrointestinal reactions, particularly nausea, as the most common adverse reactions, and notes that a sharp, unpleasant metallic taste is not unusual. The taste is harmless and fades when you stop. Furry tongue and mouth soreness can accompany a sudden Candida overgrowth during therapy, worth flagging early if itching starts partway through a course meant to fix the opposite complaint.

Now alcohol, because most of what circulates is out of date. The label still tells you to stop alcoholic beverages during treatment and for at least three days afterward, citing cramps, nausea, vomiting, headaches and flushing. The CDC's current guidelines state the opposite: refraining from alcohol use while taking metronidazole or tinidazole is unnecessary. A systematic review found that despite the widespread belief, the literature raises doubt, and the interaction occurs with unclear frequency and varying severity. Weak evidence is not a green light. Ask your prescriber.

Both forms are prescription only, so an online route means a clinician reviewing an intake before anything ships. A good intake asks what the discharge looks like, whether there is an odor and when it is worst, whether itching is present, your pregnancy status, what you have taken before, and how many episodes you have had in the past year. That last question is the one that changes the plan, so answer it precisely.

Remote handling does not fit every case. Pelvic pain, fever, bleeding between periods, pregnancy, or a first episode never confirmed by anyone are all reasons a clinician may want an examination and a swab first. A service that routes nobody to in-person care is telling you something about its intake. Whether this drug suits you, which route to use, and whether your case belongs online at all are all a prescriber's call.

In a randomized trial, women who responded to a ten-day gel induction and then used 0.75% metronidazole gel twice weekly for sixteen weeks had recurrence in 25.5% of cases against 59.1% on placebo. Across the full 28 weeks, which included twelve weeks off therapy, that gap closed to 51.0% against 75%, and vaginal candidiasis was significantly more frequent on metronidazole. Suppression buys time; it does not reset the flora.

The partner picture shifted in 2025. In an open-label randomized trial in monogamous heterosexual couples, treating the male partner with oral metronidazole plus topical clindamycin alongside the woman's first-line treatment brought recurrence within twelve weeks to 35%, against 63% when only the woman was treated. CDC guidance still does not recommend routine partner treatment. If that describes your situation and BV keeps returning, name the trial in your consult.

Medicaid's National Average Drug Acquisition Cost file, the public record of what US pharmacies pay for drugs, priced generic metronidazole 500 mg tablets at $0.10116 per tablet and generic vaginal metronidazole 0.75% gel at $0.14131 per gram in the file published on 2 September 2026. The brand-classified Vandazole listing of that same gel sits more than twice as high at $0.32347 per gram.

Run those against the CDC regimens and the seven-day oral course is about $1.42 of drug, while five nights of generic gel at 5 g each comes to roughly $3.53. Few prescriptions are cheaper.

The same file prices the alternatives: generic tinidazole 500 mg at $2.19872 a tablet, generic clindamycin 2% vaginal cream at $1.83441 per gram, and single-dose secnidazole 2 g granules, which exist only as a brand with no generic behind them, at $281.54727 per packet. So two days of tinidazole runs about $18 of drug, seven nights of clindamycin cream about $64, and the single dose roughly two hundred times the tablets it replaces. Acquisition cost is only the floor, but the floor tells you when a bundled quote is mostly service rather than medicine.

What separates services here is not the drug, since first-line metronidazole is the same molecule everywhere. It is whether the intake takes recurrence seriously. A form that asks only about today's symptoms hands you seven days of tablets and closes the file, which is fine for a first episode and close to useless if this is your third this year. Ask what happens if you are back in eight weeks, before you pay.

Then check what comes after the prescription: a follow-up that does not cost a second full consultation, and a route to in-person care if the diagnosis needs confirming. Nothing here is medical advice or a recommendation of any service, and what suits you is a licensed clinician's call. What you can judge yourself is price transparency, because a bundled quote can price a $1.42 course at a large multiple without ever showing the split.